NT-proBNP, Hs-cTnT, and CRP Predict the Risk of Cardiopulmonary Outcomes in Systemic Sclerosis: Findings from the Canadian Scleroderma Research Group
Overview
Affiliations
Objective: The aim of this study was to determine the independent value of N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein to predict onset of cardiopulmonary disease in a large, multi-center systemic sclerosis cohort followed prospectively.
Methods: Subjects from the Canadian Scleroderma Research Group registry with data on N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein were identified. Outcomes of interest were death, systolic dysfunction (left ventricular ejection fraction < 50% or medications for heart failure), pulmonary arterial hypertension by right heart catheterization, pulmonary hypertension by cardiac echocardiography (systolic pulmonary artery pressures ⩾ 45 mmHg), arrhythmias (pacemaker/implantable cardiac defibrillator or anti-arrhythmic medications), and interstitial lung disease. Multivariate Cox proportional hazard models were generated for each outcome.
Results: A total of 675 subjects were included with a mean follow-up of 3.0 ± 1.8 years. Subjects were predominantly women (88.4%) with mean age of 58.2 ± 11.3 years and mean disease duration of 13.7 ± 9.1 years. One hundred and one (101, 15%) subjects died during follow-up, 37 (6.4 %) developed systolic dysfunction, 18 (2.9%) arrhythmias, 34 (5.1%) pulmonary arterial hypertension, 43 (7.3%) pulmonary hypertension, and 48 (12.3%) interstitial lung disease. In multivariate analyses, elevated levels of N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein were associated with increased risk of death, while elevated levels of N-terminal pro b-type natriuretic peptide and C-reactive protein were associated with increased risk of developing pulmonary hypertension.
Conclusion: In systemic sclerosis, N-terminal pro b-type natriuretic peptide, high-sensitivity cardiac troponin T, and C-reactive protein have independent predictive value for death and pulmonary hypertension. A larger study would be required to determine the predictive value of these biomarkers for less common systemic sclerosis outcomes.
Dragoi I, Rezus C, Burlui A, Bratoiu I, Rezus E Medicina (Kaunas). 2025; 61(1).
PMID: 39859001 PMC: 11766816. DOI: 10.3390/medicina61010019.
Chai L, Zeng J, Gong L, Li Z, Wang F, Liu Z BMC Nephrol. 2024; 25(1):427.
PMID: 39604892 PMC: 11600683. DOI: 10.1186/s12882-024-03875-6.
Heilmeier U, Feldmann D, Leynes A, Seng M, Jandova I, Keute M Front Med (Lausanne). 2024; 11:1446268.
PMID: 39564499 PMC: 11573558. DOI: 10.3389/fmed.2024.1446268.
Progression, Management, and Outcome of Aortic Valve Stenosis in Systemic Sclerosis: A Case Series.
Vergara A, Orlando A, Caiazza E, Vettori S, Cuomo G, Argiento P J Cardiovasc Dev Dis. 2024; 11(9).
PMID: 39330332 PMC: 11432032. DOI: 10.3390/jcdd11090274.
Bazso A, Szodoray P, Shoenfeld Y, Kiss E Clin Rheumatol. 2024; 43(10):3055-3072.
PMID: 39210206 PMC: 11442557. DOI: 10.1007/s10067-024-07123-y.